Primary Aldosteronism

From Bench to Bedside: Translational Advances in Cardiovascular Disease

by Prateek Chopra | June 19, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: While the gut microbiome may influence blood pressure regulation, population-based evidence does not demonstrate a consistent link with future hypertension. Translational research is advancing our understanding of neuro-immune, inflammatory, and hormonal mechanisms in cardiovascular disease. Key Mechanistic Insights: Gut Microbiome: Rigorous sample collection, confounder control, and […]

From Bench to Bedside: Translational Advances in Cardiovascular Disease Read Post »

Leave a Comment / ESH Day 4 / bluetree.healthcare@gmail.com / July 29, 2026 / Baxdrostat, Gut Microbiome and Hypertension, Hypertension Research, Neuro-Immune Pathways, Primary Aldosteronism

Primary Aldosteronism – Wide Spectrum of Clinical Manifestations

by Prateek Chopra | June 8, 2026 | Cardiology Conferences | ESH 2026 Cardiovascular Impact of PA: Primary aldosteronism (PA) is a common, potentially curable cause of secondary hypertension. Aldosterone excess contributes to cardiovascular morbidity beyond the effects of elevated blood pressure alone, including stroke, coronary artery disease, atrial fibrillation, heart failure, left ventricular hypertrophy, arterial stiffness, and target-organ damage. Illustrative

Primary Aldosteronism – Wide Spectrum of Clinical Manifestations Read Post »

Leave a Comment / ESH Day 2 / bluetree.healthcare@gmail.com / July 29, 2026 / Aldosterone Excess, by Prateek Chopra | June 7, Cardiovascular Risk, Mineralocorticoid Receptor Antagonists (MRAs), Primary Aldosteronism, Secondary Hypertension

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism?

by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Non-steroidal mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASIs) are emerging therapeutic approaches in primary aldosteronism (PA). Evidence from randomized trials, single-arm studies, real-world analyses, and ongoing clinical programs evaluates the efficacy, biochemical outcomes, and safety of finerenone, baxdrostat, and dexfadrostat. Key Evidence – MRAs:

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism? Read Post »

Leave a Comment / ESH Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Aldosterone Synthase Inhibitors (ASI), Finerenone, Non-Steroidal Mineralocorticoid Receptor Antagonists (MRAs), Primary Aldosteronism, Resistant Hypertension